163
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Risk factors associated with competing mortality among patients with head and neck cancer in Japan

, , , , , , , , & show all
Pages 325-329 | Received 19 Sep 2015, Accepted 27 Oct 2015, Published online: 04 Dec 2015

References

  • Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011;29:3503–9.
  • Rietbergen MM, Brakenhoff RH, Bloemena E, Witte BI, Snijders PJ, Heideman DA, et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol 2013;24:2740–5.
  • Takenaka Y, Yamamoto M, Nakahara S, Yamamoto Y, Yasui T, Hanamoto A, et al. Factors associated with malnutrition in patients with head and neck cancer. Acta Otolaryngol 2014;134:1079–85.
  • World Health Organization Disease incidence, prevalence and disability 2004; Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part3.pdf.
  • Boje CR, Dalton SO, Gronborg TK, Primdahl H, Kristensen CA, Andersen E, et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol 2013;52:285–93.
  • Landis SH, El-Hariry IA, van Herk-Sukel MP, van den Haak P, Janssen-Heijnen ML, Penning-van Beest FJ, et al. Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. Head Neck 2012;34:238–44.
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
  • Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–54.
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
  • Lucs AV, Saltman B, Chung CH, Steinberg BM, Schwartz DL. Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck 2013;35:294–306.
  • Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–9.
  • Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956–62.
  • Shen W, Sakamoto N, Yang L. Cancer-specific mortality and competing mortality in patients with head and neck squamous cell carcinoma: a competing risk analysis. Ann Surg Oncol 2015;22:264–71.
  • Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 2010;28:15–20.
  • Ryu CH, Roh JL, Kim SB, Lee SW, Choi SH, Nam SY, et al. Risk factors for non-cancer health events in patients with head and neck squamous cell carcinoma. Ann Oncol 2013;24:1049–54.
  • Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011;29:739–46.
  • Hanamoto A, Takenaka Y, Shimosegawa E, Yamamoto Y, Yoshii T, Nakahara S, et al. Limitation of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer. Ann Nucl Med 2013;27: 880–5.
  • Conway DI, Brenner DR, McMahon AD, Macpherson LM, Agudo A, Ahrens W, et al. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int J Cancer 2015;136:1125–39.
  • Mell LK, Jeong JH. Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 2010;28:4297–9.
  • Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4–14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.